Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

ArriVent BioPharma (AVBP) Equity Average (2023 - 2026)

ArriVent BioPharma has reported Equity Average over the past 4 years, most recently at $315.6 million for Q1 2026.

  • Quarterly results put Equity Average at $315.6 million for Q1 2026, up 37.16% from a year ago — trailing twelve months through Mar 2026 was $315.6 million (up 37.16% YoY), and the annual figure for FY2025 was $282.4 million, up 440.75%.
  • Equity Average reached $315.6 million in Q1 2026 per AVBP's latest filing, up from $306.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $315.6 million in Q1 2026 and bottomed at -$142.9 million in Q4 2023.
  • Median Equity Average over the past 4 years was $248.8 million (2024), compared with a mean of $160.3 million.
  • The largest annual shift saw Equity Average skyrocketed 385.03% in 2024 before it decreased 26.36% in 2025.
  • Over 4 years, Equity Average stood at -$142.9 million in 2023, then surged by 287.25% to $267.6 million in 2024, then increased by 14.4% to $306.1 million in 2025, then grew by 3.1% to $315.6 million in 2026.
  • Business Quant data shows Equity Average for AVBP at $315.6 million in Q1 2026, $306.1 million in Q4 2025, and $277.4 million in Q3 2025.